Gilead utilizes machine learning to find new NASH drugs
Gilead has been trying to construct a deeper NASH pipeline as prospects dim for its lead candidate in the space. Phase 3 data released in February showed the candidate, selonsertib, didn’t significantly outperform placebo in treating NASH patients who developed compensated cirrhosis because of severe liver scarring. While another trial evaluating the drug in less sick patients has